Praxis stops EMBOLD study early after relutrigine shows efficacy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Praxis Precision Medicines Inc. (PRAX) PT Raised to $500 at Truist Securities
December 8, 2025 6:26 AM ESTTruist Securities analyst Joon Lee raised the price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX) to $500.00 (from $360.00) while maintaining a Buy rating.
The analyst comments "Vormatrigine reported 100% median seizure reduction at week 8, which was sustained through wk 16 in full Ph2 RADIANT. The results... More
